Sangamo Therapeutics Inc
NASDAQ:SGMO

Watchlist Manager
Sangamo Therapeutics Inc Logo
Sangamo Therapeutics Inc
NASDAQ:SGMO
Watchlist
Price: 1.88 USD -4.08% Market Closed
Market Cap: 391.5m USD
Have any thoughts about
Sangamo Therapeutics Inc?
Write Note

Sangamo Therapeutics Inc
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Sangamo Therapeutics Inc
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Sangamo Therapeutics Inc
NASDAQ:SGMO
Pre-Tax Income
-$183.8m
CAGR 3-Years
-1%
CAGR 5-Years
-9%
CAGR 10-Years
-20%
Abbvie Inc
NYSE:ABBV
Pre-Tax Income
$7.2B
CAGR 3-Years
0%
CAGR 5-Years
19%
CAGR 10-Years
4%
Gilead Sciences Inc
NASDAQ:GILD
Pre-Tax Income
$176m
CAGR 3-Years
-73%
CAGR 5-Years
-47%
CAGR 10-Years
-34%
Amgen Inc
NASDAQ:AMGN
Pre-Tax Income
$4.7B
CAGR 3-Years
-10%
CAGR 5-Years
-13%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Pre-Tax Income
$259.6m
CAGR 3-Years
-54%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Pre-Tax Income
$5B
CAGR 3-Years
-15%
CAGR 5-Years
18%
CAGR 10-Years
21%
No Stocks Found

Sangamo Therapeutics Inc
Glance View

Market Cap
392.2m USD
Industry
Biotechnology

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. The company is headquartered in Brisbane California, California and currently employs 431 full-time employees. The company went IPO on 2000-04-06. The firm focuses on leveraging its optimized zinc finger (ZF) technology, which is a differentiated tool used to develop genomic medicines, including allogeneic cell therapies and in vivo genome engineering therapies. Its product candidates include Isaralgagene civaparvovec, also known as ST-920, its wholly owned gene therapy product candidate for the treatment of Fabry disease; SAR445136, its ZF nuclease, gene-edited cell therapy product candidate for the treatment of sickle cell disease (SCD); TX200, its wholly owned Chimeric Antigen Receptor (CAR) engineered regulatory T cell (CAR-Treg), cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; Giroctocogene fitelparvovec, also known as SB-525, is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A.

SGMO Intrinsic Value
2.58 USD
Undervaluation 27%
Intrinsic Value
Price

See Also

What is Sangamo Therapeutics Inc's Pre-Tax Income?
Pre-Tax Income
-183.8m USD

Based on the financial report for Sep 30, 2024, Sangamo Therapeutics Inc's Pre-Tax Income amounts to -183.8m USD.

What is Sangamo Therapeutics Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
-20%

Over the last year, the Pre-Tax Income growth was 28%. The average annual Pre-Tax Income growth rates for Sangamo Therapeutics Inc have been -1% over the past three years , -9% over the past five years , and -20% over the past ten years .

Back to Top